Samsung BioLogics Co (XKRX:207940) Total Long-Term Liabilities : ₩2,537,775 Mil (As of Mar. 2025)

View and export this data going back to 2016. Start your Free Trial

What is Samsung BioLogics Co Total Long-Term Liabilities?

Total Long-Term Liabilities includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities. Samsung BioLogics Co's Total Long-Term Liabilities for the quarter that ended in Mar. 2025 was ₩2,537,775 Mil.

Samsung BioLogics Co Total Long-Term Liabilities Historical Data

The historical data trend for Samsung BioLogics Co's Total Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Samsung BioLogics Co Total Long-Term Liabilities Chart

Samsung BioLogics Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Long-Term Liabilities

Get a 7-Day Free Trial

1,236,117.07

1,871,614.00

3,416,034.30

2,057,843.98

2,578,431.86

Samsung BioLogics Co Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Long-Term Liabilities	Get a 7-Day Free Trial															1,866,876.37	1,980,449.70	1,871,030.86	2,578,431.86	2,537,774.55

Samsung BioLogics Co Total Long-Term Liabilities Calculation

Total Long-Term Liabilities represents the obiligation that incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle, excluding minority interest. It includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities.

Samsung BioLogics Co Total Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Samsung BioLogics Co's Total Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Samsung BioLogics Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Samsung BioLogics Co Ltd (XKRX:207940) » Definitions » Total Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

125, Cheomdan-daero, Yeonsu-gu, Incheon, KOR

Website

https://www.samsungbiologics.com

Founded in 2011, Samsung Biologics is a South Korean contract development and manufacturing organization with a global client base. Europe and the US contribute 90% of its total revenue. It provides end-to-end development and manufacturing services from cell line developments to final commercial manufacturing. As of 2023, Samsung Biologics had a total production capacity of 604,000 liters, one of the largest in the world. Its CDMO services account for 72.4% of its total revenue. The balance comes from subsidiary Samsung Bioepis, acquired in 2022. Samsung Bioepis is involved in developing and manufacturing biosimilars.

Samsung BioLogics Co Headlines

No Headlines